DUBLIN, Ireland, July 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc ( AVDL), a company focused on developing FT218 for narcolepsy, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday, August 9, 2019, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2019.
To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (international). The conference ID number is 4290467. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.
About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc ( AVDL) is a branded specialty pharmaceutical company. The Company’s primary focus is on the development and potential FDA approval for FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, Avadel develops and markets a portfolio of sterile injectable drugs used in the hospital setting. For more information, please visit www.avadel.com.
| Contacts: | Michael F. Kanan |
| Chief Financial Officer | |
| Phone: (636) 449-1844 | |
| Email: [email protected] | |
| Lee Roth | |
| Burns McClellan | |
| Phone: (212) 213-0006 | |
| Email: [email protected] |
